Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fibrobody siRNA Conjugate
- Development stage
- Preclinical
- Lead developer
- Linxis Biopharmaceuticals
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Fibrobody siRNA Conjugates are investigational therapeutics developed by LinXis Biopharmaceuticals that combine proprietary "Fibrobodies"—engineered antibody fragments targeting activated myofibroblasts—with small interfering RNA (siRNA) payloads. The goal is to deliver potent anti-fibrotic and anti-contractile siRNAs directly to disease-driving myofibroblasts in fibrotic conditions such as liver fibrosis, metabolic dysfunction-associated steatohepatitis (MASH), and pulmonary arterial hypertension. The mechanism of action involves targeted delivery of therapeutic siRNAs via the Fibrobodies, which are designed to recognize cell-surface markers like PDGFRB on activated myofibroblasts, thereby enhancing cellular uptake and gene silencing specifically in fibrotic tissues[1][3]. This approach aims to overcome the poor cellular uptake typically seen with naked or systemically delivered siRNAs.
- Brand names
- Fibrobody
- Other names
- Fibrobody-siRNA ConjugateFibrobody®-siRNA Conjugate
02
Targets
PDGFRB (Platelet-derived growth factor receptor beta)
Beyond the preview
Go deeper on Fibrobody siRNA Conjugate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fibrobody siRNA Conjugate.